Hepatic Impairment
Conditions
Brief summary
The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.
Interventions
DRUGLY3314814
Administered orally
Sponsors
AstraZeneca
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
\- Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening
Exclusion criteria
* Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina * Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation * Have acute unstable neuropsychiatric disease * Have active or uncontrolled neurologic disease, or clinically significant head injury
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of LY3314814 | Baseline through 240 hours after the administration of study drug | PK: AUC(0-∞) of LY3314814 |
| PK: Maximum Observed Drug Concentration (Cmax) of LY3314814 | Baseline through 240 hours after the administration of study drug | PK: Cmax of LY3314814 |
Countries
United States
Outcome results
None listed